Gastrointestinal metabolic surgery for the treatment of type 2 diabetes mellitus

World Journal of Gastroenterology

Volumn 20, Issue 39, 2014, Pages 14315-14328

  Pok, Eng Hong ^a   Lee, Wei Jei ^b  

^a UNIVERSITY MALAYA MEDICAL CENTRE   (Malaysia)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Efficacy; Gastrointestinal surgery; Glucolipotoxicity; Metabolic surgery; Prognostic factor; Type 2 diabetes mellitus

Indexed keywords

BILE ACID; GHRELIN; GLUCOSE; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL;

BARIATRIC SURGERY; BODY MASS; CALORIC RESTRICTION; CLINICAL PATHWAY; DUODENAL JEJUNAL BYPASS; GASTROINTESTINAL SURGERY; GLYCEMIC CONTROL; HUMAN; ILEAL INTERPOSITION; MEDICAL LITERATURE; META ANALYSIS (TOPIC); MICROFLORA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT INDICATION; WEIGHT REDUCTION; ADVERSE EFFECTS; ANIMAL; BLOOD; COMPLICATION; DIABETES MELLITUS, TYPE 2; ENERGY METABOLISM; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; METABOLISM; REMISSION; RISK FACTOR; TREATMENT OUTCOME;

ANIMALS; BARIATRIC SURGERY; BIOMARKERS; BLOOD GLUCOSE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; ENERGY METABOLISM; HOMEOSTASIS; HUMANS; OBESITY; PATIENT SELECTION; REMISSION INDUCTION; RISK FACTORS; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84910153604     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i39.14315     Document Type: Review

References (105)

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004; 27: 1047-1053 [ PMID: 15111519 DOI: 10.2337/diacare.27.5.1047]
2. Chan JC, Malik V, Jia W, Kadowaki T, Yajnik CS, Yoon KH, Hu FB. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. JAMA 2009; 301: 2129-2140 [ PMID: 19470990 DOI: 10.1001/jama.2009.726]
3. Xu Y, Wang L, He J, Bi Y, Li M, Wang T, Wang L, Jiang Y, Dai M, Lu J, Xu M, Li Y, Hu N, Li J, Mi S, Chen CS, Li G, Mu Y, Zhao J, Kong L, Chen J, Lai S, Wang W, Zhao W, Ning G. Prevalence and control of diabetes in Chinese adults. JAMA 2013; 310: 948-959 [ PMID: 24002281 DOI: 10.1001/jama.2013.168118]
4. Sjöström L, Lindroos AK, Peltonen M, Torgerson J, Bouchard C, Carlsson B, Dahlgren S, Larsson B, Narbro K, Sjöström CD, Sullivan M, Wedel H. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004; 351: 2683-2693 [ PMID: 15616203 DOI: 10.1056/NEJMoa035622]
5. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes 1995; 44: 1249-1258 [ PMID: 7589820 DOI: 10.2337/diab.44.11.1249]
6. Liebl A, Mata M, Eschwège E. Evaluation of risk factors for development of complications in Type II diabetes in Europe. Diabetologia 2002; 45: S23-S28 [ PMID: 12136408 DOI: 10.1007/s00125-002-0863-0]
7. Resnick HE, Foster GL, Bardsley J, Ratner RE. Achievement of American Diabetes Association clinical practice recommendations among U.S. adults with diabetes, 1999-2002: the National Health and Nutrition Examination Survey. Diabetes Care 2006; 29: 531-537 [ PMID: 16505501 DOI: 10.2337/diacare.29.03.06.dc05-1254]
8. Rubino F, Gagner M. Potential of surgery for curing type 2 diabetes mellitus. Ann Surg 2002; 236: 554-559 [ PMID: 12409659 DOI: 10.1097/01.SLA.0000032951.37471.80]
9. Buchwald H, Estok R, Fahrbach K, Banel D, Jensen MD, Pories WJ, Bantle JP, Sledge I. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med 2009; 122: 248-256.e5 [ PMID: 19272486 DOI: 10.1016/j.amjmed.2008.09.041]
10. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001; 414: 782-787 [ PMID: 11742409 DOI: 10.1038/414782a]
11. Ferrannini E, Natali A, Bell P, Cavallo-Perin P, Lalic N, Mingrone G. Insulin resistance and hypersecretion in obesity. European Group for the Study of Insulin Resistance (EGIR). J Clin Invest 1997; 100: 1166-1173 [ PMID: 9303923 DOI: 10.1172/JCI119628]
12. Bays HE, González-Campoy JM, Bray GA, Kitabchi AE, Bergman DA, Schorr AB, Rodbard HW, Henry RR. Pathogenic potential of adipose tissue and metabolic consequences of adipocyte hypertrophy and increased visceral adiposity. Expert Rev Cardiovasc Ther 2008; 6: 343-368 [ PMID: 18327995 DOI: 10.1586/14779072.6.3.343]
13. Bays HE, Laferrère B, Dixon J, Aronne L, González-Campoy JM, Apovian C, Wolfe BM. Adiposopathy and bariatric surgery: is 'sick fat' a surgical disease? Int J Clin Pract 2009; 63: 1285-1300 [ PMID: 19691612 DOI: 10.1111/j.1742-1241.2009.02151.x]
14. Bays H, Mandarino L, DeFronzo RA. Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab 2004; 89: 463-478 [ PMID: 14764748 DOI: 10.1210/jc.2003-030723]
15. Pontiroli AE, Frigè F, Paganelli M, Folli F. In morbid obesity, metabolic abnormalities and adhesion molecules correlate with visceral fat, not with subcutaneous fat: effect of weight loss through surgery. Obes Surg 2009; 19: 745-750 [ PMID: 18629594 DOI: 10.1007/s11695-008-9626-4]
16. Rubino F, Schauer PR, Kaplan LM, Cummings DE. Metabolic surgery to treat type 2 diabetes: clinical outcomes and mechanisms of action. Annu Rev Med 2010; 61: 393-411 [ PMID: 20059345 DOI: 10.1146/annurev.med.051308.105148]
17. Isbell JM, Tamboli RA, Hansen EN, Saliba J, Dunn JP, Phillips SE, Marks-Shulman PA, Abumrad NN. The importance of caloric restriction in the early improvements in insulin sensitivity after Roux-en-Y gastric bypass surgery. Diabetes Care 2010; 33: 1438-1442 [ PMID: 20368410 DOI: 10.2337/dc09-2107]
18. Lee WJ, Chong K, Chen CY, Chen SC, Lee YC, Ser KH, Chuang LM. Diabetes remission and insulin secretion after gastric bypass in patients with body mass index & lt; 35 kg/m2. Obes Surg 2011; 21: 889-895 [ PMID: 21499957 DOI: 10.1007/s11695-011-0401-6]
19. Lee WJ, Lee YC, Ser KH, Chen JC, Chen SC. Improvement of insulin resistance after obesity surgery: a comparison of gastric banding and bypass procedures. Obes Surg 2008; 18: 1119-1125 [ PMID: 18317853 DOI: 10.1007/s11695-008-9457-3]
20. Kirk E, Reeds DN, Finck BN, Mayurranjan SM, Patterson BW, Klein S. Dietary fat and carbohydrates differentially alter insulin sensitivity during caloric restriction. Gastroenterology 2009; 136: 1552-1560 [ PMID: 19208352 DOI: 10.1053/j.gastro.2009.01.048]
21. Rao RS, Yanagisawa R, Kini S. Insulin resistance and bariatric surgery. Obes Rev 2012; 13: 316-328 [ PMID: 22106981 DOI: 10.1111/j.1467-789X.2011.00955.x]
22. Campos GM, Rabl C, Peeva S, Ciovica R, Rao M, Schwarz JM, Havel P, Schambelan M, Mulligan K. Improvement in peripheral glucose uptake after gastric bypass surgery is observed only after substantial weight loss has occurred and correlates with the magnitude of weight lost. J Gastrointest Surg 2010; 14: 15-23 [ PMID: 19838759 DOI: 10.1007/s11605-009-1060-y]
23. Muscelli E, Mingrone G, Camastra S, Manco M, Pereira JA, Pareja JC, Ferrannini E. Differential effect of weight loss on insulin resistance in surgically treated obese patients. Am J Med 2005; 118: 51-57 [ PMID: 15639210 DOI: 10.1016/j.amjmed.2004.08.017]
24. Camastra S, Gastaldelli A, Mari A, Bonuccelli S, Scartabelli G, Frascerra S, Baldi S, Nannipieri M, Rebelos E, Anselmino M, Muscelli E, Ferrannini E. Early and longer term effects of gastric bypass surgery on tissue-specific insulin sensitivity and beta cell function in morbidly obese patients with and without type 2 diabetes. Diabetologia 2011; 54: 2093-2102 [ PMID: 21614570 DOI: 10.1007/s00125-011-2193-6]
25. Mari A, Manco M, Guidone C, Nanni G, Castagneto M, Mingrone G, Ferrannini E. Restoration of normal glucose tolerance in severely obese patients after bilio-pancreatic diversion: role of insulin sensitivity and beta cell function. Diabetologia 2006; 49: 2136-2143 [ PMID: 16819611 DOI: 10.1007/s00125-006-0337-x]
26. Ferrannini E, Mingrone G. Impact of different bariatric surgical procedures on insulin action and beta-cell function in type 2 diabetes. Diabetes Care 2009; 32: 514-520 [ PMID: 19246589 DOI: 10.2337/dc08-1762]
27. Guidone C, Manco M, Valera-Mora E, Iaconelli A, Gniuli D, Mari A, Nanni G, Castagneto M, Calvani M, Mingrone G. Mechanisms of recovery from type 2 diabetes after malabsorptive bariatric surgery. Diabetes 2006; 55: 2025-2031 [ PMID: 16804072 DOI: 10.2337/db06-0068]
28. Rosa G, Mingrone G, Manco M, Euthine V, Gniuli D, Calvani R, Calvani M, Favuzzi AM, Castagneto M, Vidal H. Molecular mechanisms of diabetes reversibility after bariatric surgery. Int J Obes (Lond) 2007; 31: 1429-1436 [ PMID: 17515913 DOI: 10.1038/sj.ijo.0803630]
29. Pournaras DJ, Osborne A, Hawkins SC, Vincent RP, Mahon D, Ewings P, Ghatei MA, Bloom SR, Welbourn R, le Roux CW. Remission of type 2 diabetes after gastric bypass and banding: mechanisms and 2 year outcomes. Ann Surg 2010; 252: 966-971 [ PMID: 21107106 DOI: 10.1097/SLA.0b013e3181efc49a]
30. Rubino F, Forgione A, Cummings DE, Vix M, Gnuli D, Mingrone G, Castagneto M, Marescaux J. The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg 2006; 244: 741-749 [ PMID: 17060767 DOI: 10.1097/01.sla.0000224726.61448.1b]
31. Patel SR, Hakim D, Mason J, Hakim N. The duodenal-jejunal bypass sleeve (EndoBarrier Gastrointestinal Liner) for weight loss and treatment of type 2 diabetes. Surg Obes Relat Dis 2013; 9: 482-484 [ PMID: 23452926 DOI: 10.1016/j.soard.2013.01.015]
32. Zhang XJ, Xiao Z, Yu HL, Zhang XX, Cheng Z, Tian HM. Short-term glucose metabolism and gut hormone modulations after Billroth II gastrojejunostomy in nonobese gastric cancer patients with type 2 diabetes mellitus, impaired glucose tolerance and normal glucose tolerance. Arch Med Res 2013; 44: 437-443 [ PMID: 23973197 DOI: 10.1016/j.arcmed.2013.07.004]
33. Lee WJ, Chong K, Ser KH, Lee YC, Chen SC, Chen JC, Tsai MH, Chuang LM. Gastric bypass vs sleeve gastrectomy for type 2 diabetes mellitus: a randomized controlled trial. Arch Surg 2011; 146: 143-148 [ PMID: 21339423 DOI: 10.1001/archsurg.2010. 326]
34. Schauer PR, Kashyap SR, Wolski K, Brethauer SA, Kirwan JP, Pothier CE, Thomas S, Abood B, Nissen SE, Bhatt DL. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. N Engl J Med 2012; 366: 1567-1576 [ PMID: 22449319 DOI: 10.1056/NEJMoa1200225]
35. Melissas J, Leventi A, Klinaki I, Perisinakis K, Koukouraki S, de Bree E, Karkavitsas N. Alterations of global gastrointestinal motility after sleeve gastrectomy: a prospective study. Ann Surg 2013; 258: 976-982 [ PMID: 23160151 DOI: 10.1097/SLA.0b013e3182774522]
36. Orskov C, Wettergren A, Holst JJ. Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day. Scand J Gastroenterol 1996; 31: 665-670 [ PMID: 8819215 DOI: 10.3109/00365529609009147]
37. Farilla L, Bulotta A, Hirshberg B, Li Calzi S, Khoury N, Noushmehr H, Bertolotto C, Di Mario U, Harlan DM, Perfetti R. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 2003; 144: 5149-5158 [ PMID: 12960095 DOI: 10.1210/en.2003-0323]
38. Drucker DJ. Glucagon-like peptide-1 and the islet beta-cell: augmentation of cell proliferation and inhibition of apoptosis. Endocrinology 2003; 144: 5145-5148 [ PMID: 14645210 DOI: 10.1210/en.2003-1147]
39. Schwartz S, DeFronzo RA. Is incretin-based therapy ready for the care of hospitalized patients with type 2 diabetes?: The time has come for GLP-1 receptor agonists! Diabetes Care 2013; 36: 2107-2111 [ PMID: 23801800 DOI: 10.2337/dc12-2060]
40. Tinoco A, El-Kadre L, Aquiar L, Tinoco R, Savassi-Rocha P. Short-term and mid-term control of type 2 diabetes mellitus by laparoscopic sleeve gastrectomy with ileal interposition. World J Surg 2011; 35: 2238-2244 [ PMID: 21744166 DOI: 10.1007/s00268-011-1188-2]
41. Geloneze B, Tambascia MA, Pilla VF, Geloneze SR, Repetto EM, Pareja JC. Ghrelin: a gut-brain hormone: effect of gastric bypass surgery. Obes Surg 2003; 13: 17-22 [ PMID: 12630608 DOI: 10.1381/096089203321136539]
42. Cummings DE, Shannon MH. Roles for ghrelin in the regulation of appetite and body weight. Arch Surg 2003; 138: 389-396 [ PMID: 12686525 DOI: 10.1001/archsurg.138.4.389]
43. Broglio F, Arvat E, Benso A, Gottero C, Muccioli G, Papotti M, van der Lely AJ, Deghenghi R, Ghigo E. Ghrelin, a natural GH secretagogue produced by the stomach, induces hyperglycemia and reduces insulin secretion in humans. J Clin Endocrinol Metab 2001; 86: 5083-5086 [ PMID: 11600590 DOI: 10.1210/jc.86.10.5083]
44. Tymitz K, Engel A, McDonough S, Hendy MP, Kerlakian G. Changes in ghrelin levels following bariatric surgery: review of the literature. Obes Surg 2011; 21: 125-130 [ PMID: 21104455 DOI: 10.1007/s11695-010-0311-z]
45. Patrikakos P, Toutouzas KG, Gazouli M, Perrea D, Menenakos E, Papadopoulos S, Zografos G. Long-term plasma ghrelin and leptin modulation after sleeve gastrectomy in Wistar rats in comparison with gastric tissue ghrelin expression. Obes Surg 2011; 21: 1432-1437 [ PMID: 21611877 DOI: 10.1007/s11695-011-0426-x]
46. Neuschwander-Tetri BA. Farnesoid x receptor agonists: what they are and how they might be used in treating liver disease. Curr Gastroenterol Rep 2012; 14: 55-62 [ PMID: 22094889 DOI: 10.1007/s11894-011-0232-6]
47. Teodoro JS, Rolo AP, Palmeira CM. Hepatic FXR: key regulator of whole-body energy metabolism. Trends Endocrinol Metab 2011; 22: 458-466 [ PMID: 21862343 DOI: 10.1016/j.tem.2011.07.002]
48. Stepanov V, Stankov K, Mikov M. The bile acid membrane receptor TGR5: a novel pharmacological target in metabolic, inflammatory and neoplastic disorders. J Recept Signal Transduct Res 2013; 33: 213-223 [ PMID: 23782454 DOI: 10.3109/10799893.2013.802805]
49. Parker HE, Wallis K, le Roux CW, Wong KY, Reimann F, Gribble FM. Molecular mechanisms underlying bile acid-stimulated glucagon-like peptide-1 secretion. Br J Pharmacol 2012; 165: 414-423 [ PMID: 21718300 DOI: 10.1111/j.1476-5381.2011.01561.x]
50. Ooi CP, Loke SC. Colesevelam for Type 2 diabetes mellitus: an abridged Cochrane review. Diabet Med 2014; 31: 2-14 [ PMID: 24024701 DOI: 10.1111/dme.12295]
51. Pournaras DJ, Glicksman C, Vincent RP, Kuganolipava S, Alaghband-Zadeh J, Mahon D, Bekker JH, Ghatei MA, Bloom SR, Walters JR, Welbourn R, le Roux CW. The role of bile after Roux-en-Y gastric bypass in promoting weight loss and improving glycaemic control. Endocrinology 2012; 153: 3613-3619 [ PMID: 22673227 DOI: 10.1210/en.2011-2145]
52. Kootte RS, Vrieze A, Holleman F, Dallinga-Thie GM, Zoetendal EG, de Vos WM, Groen AK, Hoekstra JB, Stroes ES, Nieuwdorp M. The therapeutic potential of manipulating gut microbiota in obesity and type 2 diabetes mellitus. Diabetes Obes Metab 2012; 14: 112-120 [ PMID: 21812894 DOI: 10.1111/j.1463-1326.2011.01483.x]
53. Naito E, Yoshida Y, Makino K, Kounoshi Y, Kunihiro S, Takahashi R, Matsuzaki T, Miyazaki K, Ishikawa F. Beneficial effect of oral administration of Lactobacillus casei strain Shirota on insulin resistance in diet-induced obesity mice. J Appl Microbiol 2011; 110: 650-657 [ PMID: 21281408 DOI: 10.1111/j.1365-2672.2010.04922.x]
54. Kang JH, Yun SI, Park HO. Effects of Lactobacillus gasseri BNR17 on body weight and adipose tissue mass in diet-induced overweight rats. J Microbiol 2010; 48: 712-714 [ PMID: 21046354 DOI: 10.1007/s12275-010-0363-8]
55. Sjöström L, Peltonen M, Jacobson P, Sjöström CD, Karason K, Wedel H, Ahlin S, Anveden A˚, Bengtsson C, Bergmark G, Bouchard C, Carlsson B, Dahlgren S, Karlsson J, Lindroos AK, Lönroth H, Narbro K, Näslund I, Olbers T, Svensson PA, Carlsson LM. Bariatric surgery and long-term cardiovascular events. JAMA 2012; 307: 56-65 [ PMID: 22215166 DOI: 10.1001/jama.2011.1914]
56. Sjöström L, Narbro K, Sjöström CD, Karason K, Larsson B, Wedel H, Lystig T, Sullivan M, Bouchard C, Carlsson B, Bengtsson C, Dahlgren S, Gummesson A, Jacobson P, Karlsson J, Lindroos AK, Lönroth H, Näslund I, Olbers T, Stenlöf K, Torgerson J, Agren G, Carlsson LM. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007; 357: 741-752 [ PMID: 17715408 DOI: 10.1056/NEJMoa066254]
57. Dixon JB, O'Brien PE, Playfair J, Chapman L, Schachter LM, Skinner S, Proietto J, Bailey M, Anderson M. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA 2008; 299: 316-323 [ PMID: 18212316 DOI: 10.1001/jama.299.3.316]
58. Ikramuddin S, Korner J, Lee WJ, Connett JE, Inabnet WB, Billington CJ, Thomas AJ, Leslie DB, Chong K, Jeffery RW, Ahmed L, Vella A, Chuang LM, Bessler M, Sarr MG, Swain JM, Laqua P, Jensen MD, Bantle JP. Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the Diabetes Surgery Study randomized clinical trial. JAMA 2013; 309: 2240-2249 [ PMID: 23736733 DOI: 10.1001/jama.2013.5835]
59. Shah SS, Todkar JS, Shah PS, Cummings DE. Diabetes remission and reduced cardiovascular risk after gastric bypass in Asian Indians with body mass index & lt; 35 kg/m(2). Surg Obes Relat Dis 2010; 6: 332-338 [ PMID: 19846351 DOI: 10.1016/j.soard.2009.08.009]
60. Huang CK, Shabbir A, Lo CH, Tai CM, Chen YS, Houng JY. Laparoscopic Roux-en-Y gastric bypass for the treatment of type II diabetes mellitus in Chinese patients with body mass index of 25-35. Obes Surg 2011; 21: 1344-1349 [ PMID: 21479764 DOI: 10.1007/s11695-011-0408-z]
61. Lee WJ, Hur KY, Lakadawala M, Kasama K, Wong SK, Lee YC. Gastrointestinal metabolic surgery for the treatment of diabetic patients: a multi-institutional international study. J Gastrointest Surg 2012; 16: 45-51; discussion 51-52 [ PMID: 22042564 DOI: 10.1007/s11605-011-1740-2]
62. Scopinaro N, Adami GF, Papadia FS, Camerini G, Carlini F, Fried M, Briatore L, D'Alessandro G, Andraghetti G, Cordera R. Effects of biliopanceratic diversion on type 2 diabetes in patients with BMI 25 to 35. Ann Surg 2011; 253: 699-703 [ PMID: 21475009 DOI: 10.1097/SLA.0b013e318203ae44]
63. Maggard-Gibbons M, Maglione M, Livhits M, Ewing B, Maher AR, Hu J, Li Z, Shekelle PG. Bariatric surgery for weight loss and glycemic control in nonmorbidly obese adults with diabetes: a systematic review. JAMA 2013; 309: 2250-2261 [ PMID: 23736734 DOI: 10.1001/jama.2013.4851]
64. Cohen RV, Pinheiro JC, Schiavon CA, Salles JE, Wajchenberg BL, Cummings DE. Effects of gastric bypass surgery in patients with type 2 diabetes and only mild obesity. Diabetes Care 2012; 35: 1420-1428 [ PMID: 22723580 DOI: 10.2337/dc11-2289]
65. Kadera BE, Lum K, Grant J, Pryor AD, Portenier DD, De-Maria EJ. Remission of type 2 diabetes after Roux-en-Y gastric bypass is associated with greater weight loss. Surg Obes Relat Dis 2009; 5: 305-309 [ PMID: 19460674 DOI: 10.1016/j.soard.2009.02.007]
66. Dixon JB, Hur KY, Lee WJ, Kim MJ, Chong K, Chen SC, Straznicky NE, Zimmet P. Gastric bypass in Type 2 diabetes with BMI & lt; 30: weight and weight loss have a major influence on outcomes. Diabet Med 2013; 30: e127-e134 [ PMID: 23278432 DOI: 10.1111/dme.12107]
67. Rubino F, Kaplan LM, Schauer PR, Cummings DE. The Diabetes Surgery Summit consensus conference: recommendations for the evaluation and use of gastrointestinal surgery to treat type 2 diabetes mellitus. Ann Surg 2010; 251: 399-405 [ PMID: 19934752 DOI: 10.1097/SLA.0b013e3181be34e7]
68. American Diabetes Association. Standards of medical care in diabetes - 2013. Diabetes Care 2013; 36 Suppl 1: S11-S66 [ PMID: 23264422 DOI: 10.2337/dc13-S011]
69. Haslam DW, James WP. Obesity. Lancet 2005; 366: 1197-1209 [ PMID: 16198769 DOI: 10.1016/S0140-6736(05)67483-1]
70. Cohen R, Caravatto PP, Correa JL, Noujaim P, Petry TZ, Salles JE, Schiavon CA. Glycemic control after stomach-sparing duodenal-jejunal bypass surgery in diabetic patients with low body mass index. Surg Obes Relat Dis 2012; 8: 375-380 [ PMID: 22410638 DOI: 10.1016/j.soard.2012.01.017]
71. Geloneze B, Geloneze SR, Chaim E, Hirsch FF, Felici AC, Lambert G, Tambascia MA, Pareja JC. Metabolic surgery for non-obese type 2 diabetes: incretins, adipocytokines, and insulin secretion/resistance changes in a 1-year interventional clinical controlled study. Ann Surg 2012; 256: 72-78 [ PMID: 22664560 DOI: 10.1097/SLA.0b013e3182592c62]
72. Lee HC, Kim MK, Kwon HS, Kim E, Song KH. Early changes in incretin secretion after laparoscopic duodenal-jejunal bypass surgery in type 2 diabetic patients. Obes Surg 2010; 20: 1530-1535 [ PMID: 20803098 DOI: 10.1007/s11695-010-0248-2]
73. Lee WJ, Ser KH, Chong K, Lee YC, Chen SC, Tsou JJ, Chen JC, Chen CM. Laparoscopic sleeve gastrectomy for diabetes treatment in nonmorbidly obese patients: efficacy and change of insulin secretion. Surgery 2010; 147: 664-669 [ PMID: 20004451 DOI: 10.1016/j.surg.2009.10.059]
74. Pories WJ, Dohm LG, Mansfield CJ. Beyond the BMI: the search for better guidelines for bariatric surgery. Obesity (Silver Spring) 2010; 18: 865-871 [ PMID: 20150899 DOI: 10.1038/oby.2010.8]
75. Fabbrini E, Magkos F, Mohammed BS, Pietka T, Abumrad NA, Patterson BW, Okunade A, Klein S. Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc Natl Acad Sci USA 2009; 106: 15430-15435 [ PMID: 19706383 DOI: 10.1073/pnas.0904944106]
76. Gallagher D, Kelley DE, Yim JE, Spence N, Albu J, Boxt L, Pi-Sunyer FX, Heshka S. Adipose tissue distribution is different in type 2 diabetes. Am J Clin Nutr 2009; 89: 807-814 [ PMID: 19158213 DOI: 10.3945/ajcn.2008.26955]
77. Sjöholm K, Anveden A, Peltonen M, Jacobson P, Romeo S, Svensson PA, Sjöström L, Carlsson LM. Evaluation of current eligibility criteria for bariatric surgery: diabetes prevention and risk factor changes in the Swedish obese subjects (SOS) study. Diabetes Care 2013; 36: 1335-1340 [ PMID: 23359358 DOI: 10.2337/dc12-1395]
78. Lee WJ, Chong K, Ser KH, Chen JC, Lee YC, Chen SC, Su YH, Tsai MH. C-peptide predicts the remission of type 2 diabetes after bariatric surgery. Obes Surg 2012; 22: 293-298 [ PMID: 22139820 DOI: 10.1007/s11695-011-0565-0]
79. Thaler JP, Cummings DE. Minireview: Hormonal and metabolic mechanisms of diabetes remission after gastrointestinal surgery. Endocrinology 2009; 150: 2518-2525 [ PMID: 19372197 DOI: 10.1210/en.2009-0367]
80. Kasama K, Tagaya N, Kanehira E, Oshiro T, Seki Y, Kinouchi M, Umezawa A, Negishi Y, Kurokawa Y. Laparoscopic sleeve gastrectomy with duodenojejunal bypass: technique and preliminary results. Obes Surg 2009; 19: 1341-1345 [ PMID: 19626382 DOI: 10.1007/s11695-009-9873-z]
81. Lee WJ, Lee KT, Kasama K, Seiki Y, Ser KH, Chun SC, Chen JC, Lee YC. Laparoscopic single-anastomosis duodenaljejunal bypass with sleeve gastrectomy (SADJB-SG): short-term result and comparison with gastric bypass. Obes Surg 2014; 24: 109-113 [ PMID: 23990452 DOI: 10.1007/s11695-013-1067-z]
82. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 1995; 44: 968-983 [ PMID: 7622004 DOI: 10.2337/diab.44.8.968]
83. Dixon JB, Chuang LM, Chong K, Chen SC, Lambert GW, Straznicky NE, Lambert EA, Lee WJ. Predicting the glycemic response to gastric bypass surgery in patients with type 2 diabetes. Diabetes Care 2013; 36: 20-26 [ PMID: 23033249 DOI: 10.2337/dc12-0779]
84. Stern MP, Williams K, González-Villalpando C, Hunt KJ, Haffner SM. Does the metabolic syndrome improve identification of individuals at risk of type 2 diabetes and/or cardiovascular disease? Diabetes Care 2004; 27: 2676-2681 [ PMID: 15505004 DOI: 10.2337/diacare.27.11.2676]
85. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome - a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006; 23: 469-480 [ PMID: 16681555 DOI: 10.1111/j.1464-5491.2006.01858.x]
86. Buchwald H, Estok R, Fahrbach K, Banel D, Sledge I. Trends in mortality in bariatric surgery: a systematic review and meta-analysis. Surgery 2007; 142: 621-632; discussion 632-635 [ PMID: 17950357 DOI: 10.1016/j.surg.2007.07.018]
87. Inabnet WB, Winegar DA, Sherif B, Sarr MG. Early outcomes of bariatric surgery in patients with metabolic syndrome: an analysis of the bariatric outcomes longitudinal database. J Am Coll Surg 2012; 214: 550-556; discussion 556-557 [ PMID: 22321517 DOI: 10.1016/j.jamcollsurg.2011.12.019]
88. DiGiorgi M, Rosen DJ, Choi JJ, Milone L, Schrope B, Olivero-Rivera L, Restuccia N, Yuen S, Fisk M, Inabnet WB, Bessler M. Re-emergence of diabetes after gastric bypass in patients with mid- to long-term follow-up. Surg Obes Relat Dis 2010; 6: 249-253 [ PMID: 20510288 DOI: 10.1016/j.soard.2009.09.019]
89. Chikunguwo SM, Wolfe LG, Dodson P, Meador JG, Baugh N, Clore JN, Kellum JM, Maher JW. Analysis of factors associated with durable remission of diabetes after Roux-en-Y gastric bypass. Surg Obes Relat Dis 2010; 6: 254-259 [ PMID: 20303324 DOI: 10.1016/j.soard.2009.11.003]
90. Gerstein HC, Miller ME, Byington RP, Goff DC, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH, Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545-2559 [ PMID: 18539917 DOI: 10.1056/NEJMoa0802743]
91. Patel A, MacMahon S, Chalmers J, Neal B, Billot L, Woodward M, Marre M, Cooper M, Glasziou P, Grobbee D, Hamet P, Harrap S, Heller S, Liu L, Mancia G, Mogensen CE, Pan C, Poulter N, Rodgers A, Williams B, Bompoint S, de Galan BE, Joshi R, Travert F. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008; 358: 2560-2572 [ PMID: 18539916 DOI: 10.1056/NEJMoa0802987]
92. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837-853 [ PMID: 9742976 DOI: 10.1016/s0140-6736(98)07019-6]
93. Chalmers J, Cooper ME. UKPDS and the legacy effect. N Engl J Med 2008; 359: 1618-1620 [ PMID: 18843126 DOI: 10.1056/NEJMe0807625]
94. Pournaras DJ, Aasheim ET, Søvik TT, Andrews R, Mahon D, Welbourn R, Olbers T, le Roux CW. Effect of the definition of type II diabetes remission in the evaluation of bariatric surgery for metabolic disorders. Br J Surg 2012; 99: 100-103 [ PMID: 22021090 DOI: 10.1002/bjs.7704]
95. Schauer PR, Burguera B, Ikramuddin S, Cottam D, Gourash W, Hamad G, Eid GM, Mattar S, Ramanathan R, Barinas-Mitchel E, Rao RH, Kuller L, Kelley D. Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. Ann Surg 2003; 238: 467-484; discussion 84-85 [ PMID: 14530719 DOI: 10.1097/01.sla.0000089851.41115.1b]
96. Hall TC, Pellen MG, Sedman PC, Jain PK. Preoperative factors predicting remission of type 2 diabetes mellitus after Rouxen-Y gastric bypass surgery for obesity. Obes Surg 2010; 20: 1245-1250 [ PMID: 20524158 DOI: 10.1007/s11695-010-0198-8]
97. Chen SB, Lee YC, Ser KH, Chen JC, Chen SC, Hsieh HF, Lee WJ. Serum C-reactive protein and white blood cell count in morbidly obese surgical patients. Obes Surg 2009; 19: 461-466 [ PMID: 18651197 DOI: 10.1007/s11695-008-9619-3]
98. Lee WJ, Hur KY, Lakadawala M, Kasama K, Wong SK, Chen SC, Lee YC, Ser KH. Predicting success of metabolic surgery: age, body mass index, C-peptide, and duration score. Surg Obes Relat Dis 2013; 9: 379-384 [ PMID: 22963817 DOI: 10.1016/j.soard.2012.07.015]
99. Geloneze B, Geloneze SR, Fiori C, Stabe C, Tambascia MA, Chaim EA, Astiarraga BD, Pareja JC. Surgery for nonobese type 2 diabetic patients: an interventional study with duodenal-jejunal exclusion. Obes Surg 2009; 19: 1077-1083 [ PMID: 19475464 DOI: 10.1007/s11695-009-9844-4]
100. de Moura EG, Martins BC, Lopes GS, Orso IR, de Oliveira SL, Galvão Neto MP, Santo MA, Sakai P, Ramos AC, Garrido Júnior AB, Mancini MC, Halpern A, Cecconello I. Metabolic improvements in obese type 2 diabetes subjects implanted for 1 year with an endoscopically deployed duodenal-jejunal bypass liner. Diabetes Technol Ther 2012; 14: 183-189 [ PMID: 21932999 DOI: 10.1089/dia.2011.0152]
101. DePaula AL, Stival AR, DePaula CC, Halpern A, Vencio S. Surgical treatment of type 2 diabetes in patients with BMI below 35: mid-term outcomes of the laparoscopic ileal interposition associated with a sleeve gastrectomy in 202 consecutive cases. J Gastrointest Surg 2012; 16: 967-976 [ PMID: 22350720 DOI: 10.1007/s11605-011-1807-0]
102. DePaula AL, Macedo AL, Rassi N, Machado CA, Schraibman V, Silva LQ, Halpern A. Laparoscopic treatment of type 2 diabetes mellitus for patients with a body mass index less than 35. Surg Endosc 2008; 22: 706-716 [ PMID: 17704886 DOI: 10.1007/s00464-007-9472-9]
103. Kahn SE. Beta cell failure: causes and consequences. Int J Clin Pract Suppl 2001; ( 123): 13-18 [ PMID: 11594291]
104. Rubino F, Shukla A, Pomp A, Moreira M, Ahn SM, Dakin G. Bariatric, metabolic, and diabetes surgery: what's in a name? Ann Surg 2014; 259: 117-122 [ PMID: 23314274 DOI: 10.1097/SLA.0b013e3182759656]
105. Mingrone G, Panunzi S, De Gaetano A, Guidone C, Iaconelli A, Leccesi L, Nanni G, Pomp A, Castagneto M, Ghirlanda G, Rubino F. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med 2012; 366: 1577-1585 [ PMID: 22449317 DOI: 10.1056/NEJMoa1200111]